Indivior, a UK-based, global pharmaceutical company, entered into a refinancing agreement, which would allow the company to extend the maturity date on its existing term loan, according to Bloomberg.
The refinancing is designed to improve Indivior’s liquidity position by over $250 million; Indivior upsized its term debt to $350 and added a $50 million revolver, the article says.
